LISTING OF THE CLAIMS

1-7. (Canceled)

8. (Previously Presented) A method of inhibiting angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis, said method comprising:

systemically administering to said host an effective amount of a Ca2+/calcineurin/NF-ATc inhibitory agent to inhibit angiogenesis/vascular development in said host having a condition associated with unwanted angiogenesis.

9. (Original) The method according to Claim 8, wherein said agent is an NF-ATc antagonist.

10. (Original) The method according to Claim 9, wherein said agent inhibits phosphorylation of NF-ATc.

11. (Original) The method according to Claim 10, wherein said agent inhibits NF-ATc phosphorylation by binding to calcineurin.

12-14. (Canceled)

15. (Previously Presented) A method of inhibiting tumor growth in a host having a neoplastic disease condition, said method comprising:

systemically administering to said host having a neoplastic disease condition an effective amount of a Ca2+/calcineurin/NF-ATc inhibitory agent to inhibit tumor growth in said host.

16. (Original) The method according to Claim 15, wherein said agent is an NF-ATc antagonist.

17. (Original) The method according to Claim 16, wherein said agent inhibits phosphorylation of NF-ATc.

18. (Original) The method according to Claim 16, wherein said agent inhibits NF-ATc phosphorylation by binding to calcineurin.

19-34. (Canceled)

35. (Previously Presented) The method according to Claim 8, wherein said agent is FK506 or a synthetic mimetic thereof.

36. (Previously Presented) The method according to Claim 8, wherein said agent is rapamycin or a synthetic mimetic thereof.

37. (Previously Presented) The method according to Claim 8, wherein said agent is a cyclosporin.

38. (Previously Presented) The method according to Claim 37, wherein said cyclosporin is cyclosporin A.

39. (Previously Presented) The method according to Claim 38, wherein said cyclosporin is a synthetic derivative or mimetic of cyclosporin A.

40. (Previously Presented) The method according to Claim 15, wherein said agent is FK506 or a synthetic mimetic thereof.

41. (Previously Presented) The method according to Claim 15, wherein said agent is rapamycin or a synthetic mimetic thereof.

42. (Previously Presented) The method according to Claim 15, wherein said agent is a cyclosporin.

43. (Previously Presented) The method according to Claim 42, wherein said cyclosporin is cyclosporin A.

44. (Previously Presented) The method according to Claim 42, wherein said cyclosporin is a synthetic derivative or mimetic of cyclosporin A.

45. (Canceled)

46. (Previously Presented) A method of inhibiting angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis, said method comprising:

administering to said host an effective amount of a cyclosporin to inhibit angiogenesis/vascular development in a host having a condition associated with unwanted angiogenesis.

47. (Previously Presented) A method of inhibiting tumor growth in a host having a neoplastic disease condition, said method comprising:

administering to said host an effective amount of a cyclosporin to inhibit tumor growth in said host having a neoplastic disease condition.